Insights on the interaction mechanism of brigatinib to human α-1-acid glycoprotein: Experimental and computational approaches

Bao-Li Wang,Song-Bo Kou,Zhen-Yi Lin,Jie-Hua Shi,Ying-Xin Liu

DOI: https://doi.org/10.1016/j.ijbiomac.2020.04.151

IF: 8.2

2020-08-01

International Journal of Biological Macromolecules

Abstract:<p>Brigatinib, a multi-target kinase inhibitor, is primarily used to treat anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) who have previously received crizotinib or are resistant to crizotinib. In this study, we focused on elucidating the interaction mechanism between brigatinib and human alpha-1-acid glycoprotein (HAG) through experimental and computational approaches. Steady-state fluorescence and UV–vis spectroscopy measurements revealed that brigatinib could quench the intrinsic fluorescence of HAG in a static quenching manner and formed the brigatinib-HAG complex with the stoichiometric ratio of 1:1. The findings revealed that brigatinib had a stronger affinity on HAG due to higher binding constant of 2.91 × 10⁵ M⁻¹ at 298 K. It can be proved from thermodynamic parameter analysis that brigatinib spontaneously bound to HAG in the means of enthalpy driven, the main forces for stabilizing brigatinib-HAG complexes were hydrogen bonding and hydrophobic interactions. The experimental results also indicated that the binding interaction induced micro-environmental changes around tryptophan residues and the alteration in secondary structure of HAG. The presence of metal ions like Mg²⁺, Zn²⁺, Ca²⁺, Ni²⁺ and Co²⁺ affects the binding interaction and thus change the therapeutic efficacy of brigatinib. Molecular docking results suggested that brigatinib was embedded to the hydrophobic cavity of HAG. The experimental and computational results certified that hydrogen bonding and hydrophobic interaction as well as electrostatic energy and van der Waals forces plays a leading role in the binding process.</p>

polymer science,biochemistry & molecular biology,chemistry, applied

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the interaction mechanism between brigatinib and human α - 1 - acid glycoprotein (HAG). Specifically, through experimental and computational methods, the researchers aim to understand the following points:

1. **Fluorescence quenching mechanism**: Study the quenching mechanism of HAG's intrinsic fluorescence by brigatinib and determine whether it is static quenching or dynamic quenching.
2. **Binding affinity**: Measure the binding constant between brigatinib and HAG and evaluate their binding affinity.
3. **Main driving force**: Analyze through thermodynamic parameters to determine the roles of hydrogen bonds, hydrophobic interactions, etc. in the binding process.
4. **Conformational change**: Study the conformational change of HAG, especially the change of the micro - environment, after brigatinib binds to HAG.
5. **Influence of metal ions**: Explore the influence of different metal ions (such as Mg²⁺, Zn²⁺, Ca²⁺, Ni²⁺, Co²⁺) on the binding of brigatinib and HAG.

Through these studies, the author hopes to provide detailed theoretical support for the transportation, distribution behavior, pharmacodynamics and pharmacokinetics of brigatinib.